Fixed-duration (12 cycles) Venetoclax/ Obinutuzumab vs. fixed-duration (15 cycles) Venetoclax/ Pirtobrutinib vs. MRD-guided Veneto-clax/Pirtobrutinib in patients with previously untreated CLL/SLL aiming to establish Measurement Of Individual Residual disease for Adjustment of treatment duration to Improve outcomes
Fixed-duration (12 cycles) Venetoclax/ Obinutuzumab vs. fixed-duration (15 cycles) Venetoclax/ Pirtobrutinib vs. MRD-guided Veneto-clax/Pirtobrutinib in patients with previously untreated CLL/SLL aiming to establish Measurement Of Individual Residual disease for Adjustment of treatment duration to Improve outcomes
